http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Surgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance System
-
Surgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance System
-
Surgalign to Exhibit at the Society for Minimally Invasive Spine Surgery (“SMISS”) Annual Forum and the North American Spine Society (“NASS”) 2022 Annual Meeting
-
Surgalign to Exhibit at the Society for Minimally Invasive Spine Surgery (“SMISS”) Annual Forum and the North American Spine Society (“NASS”) 2022 Annual Meeting
-
Surgalign Announces FDA 510(k) Clearance of the Cortera™ Spinal Fixation System – The Company’s New Flagship Posterior Fixation Platform
-
Surgalign Announces FDA 510(k) Clearance of the Cortera™ Spinal Fixation System – The Company’s New Flagship Posterior Fixation Platform
-
Surgalign Holdings (SRGA) Enters Global Settlement Agreement with Resolve Surgical Technologies and RTI Surgical
-
Surgalign Announces Global Settlement Agreement with Resolve Surgical Technologies and RTI Surgical, Inc.
-
Surgalign Announces Global Settlement Agreement with Resolve Surgical Technologies and RTI Surgical, Inc.
-
Surgalign Holdings, Inc. Announces Second Quarter 2022 Results and Reiterates Full Year 2022 Revenue Guidance Range
-
Surgalign Holdings, Inc. Announces Second Quarter 2022 Results and Reiterates Full Year 2022 Revenue Guidance Range
-
Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary
-
Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary
-
Surgalign Reaches Settlement with the Securities and Exchange Commission on Matters Related to Prior Management Between 2015-2019
-
Surgalign Reaches Settlement with the Securities and Exchange Commission on Matters Related to Prior Management Between 2015-2019
-
Surgalign Schedules Second Quarter 2022 Earnings Release for August 9, 2022
-
Surgalign Schedules Second Quarter 2022 Earnings Release for August 9, 2022
-
Surgalign Announces the Commercial Relaunch of its Next Generation CervAlign Anterior Cervical Plate System Optimized for Discectomy and Fusion Procedures
-
Surgalign Announces the Commercial Relaunch of its Next Generation CervAlign Anterior Cervical Plate System Optimized for Discectomy and Fusion Procedures
-
Surgalign Announces Partnership with PRIA Healthcare to Improve Patient Healthcare Coverage
-
Surgalign Announces Partnership with PRIA Healthcare to Improve Patient Healthcare Coverage
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings (SRGA) Announces Clinical Site Expansion in the Commercialization of HOLO Portal
-
Surgalign™ Announces Clinical Site Expansion in the Commercialization of its HOLO Portal™ Surgical Guidance System in Ohio
-
Surgalign™ Announces Clinical Site Expansion in the Commercialization of its HOLO Portal™ Surgical Guidance System in Ohio
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings (SRGA) Announces 1:30 Reverse Stock Split
-
Surgalign Holdings, Inc. Announces 1-for-30 Reverse Stock Split
-
Surgalign Holdings, Inc. Announces 1-for-30 Reverse Stock Split
-
Surgalign Holdings, Inc. Announces First Quarter 2022 Results and Raises Full Year 2022 Revenue Guidance Range
-
Surgalign Holdings, Inc. Announces First Quarter 2022 Results and Raises Full Year 2022 Revenue Guidance Range
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings (SRGA) Announces the First Successful Surgical Procedure Utilizing its HOLO Portal™ Surgical Guidance System
-
Surgalign™ Announces the First Successful Surgical Procedure Utilizing its HOLO Portal™ Surgical Guidance System
-
Surgalign™ Announces the First Successful Surgical Procedure Utilizing its HOLO Portal™ Surgical Guidance System
-
Surgalign Holdings, Inc. Schedules First Quarter 2022 Earnings Release for May 10, 2022
-
Surgalign Holdings, Inc. Schedules First Quarter 2022 Earnings Release for May 10, 2022
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
New EVoluSIon Study Data Demonstrates Strong Support for the SImmetry® Sacroiliac Joint Fusion System
-
New EVoluSIon Study Data Demonstrates Strong Support for the SImmetry® Sacroiliac Joint Fusion System
-
Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2021 Results
-
Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2021 Results
-
Surgalign Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release for March 15, 2022
-
Surgalign Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release for March 15, 2022
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

